European CHMP recommends approval of generic sunitinib (Sunitinib Accord)
Studies have demonstrated the satisfactory quality of Sunitinib Accord, and its bioequivalence to the reference product Sutent with a license recommended for the same indications.
Source:
European Medicines Agency